Asahi Songwon Colors Limited Overview
Asahi Songwon Colors is a promoter-controlled Gujarat chemicals micro-cap (67.00% promoter holding, no pledge). It began as a single-product, single-site producer of copper phthalocyanine (CPC) blue pigments for the printing-ink industry. It is now a three-vertical group:
Phthalocyanine blue pigments: (Padra): backward-integrated into CPC blue crude.
Azo pigments: (Dahej): made through Asahi Tennants Color, a 51%-owned joint venture with Tennants Textile Colours (UK).
Active pharmaceutical ingredients (APIs): (Odhav and Chhatral): made through wholly owned Atlas Life Sciences, led by Pregabalin.
The core blue business supplies multinational ink and coatings majors, including DIC, Sun Chemical, Clariant and BASF (per CARE Ratings). It runs at 80–85% utilisation and generates the group's cash. The two newer engines turned EBITDA-positive in FY26 after a debt-funded investment cycle that took borrowings to a peak of about ₹220 crore.
Management's stated agenda, "Calibrated for growth", targets ₹1,000 crore revenue and about ₹100 crore EBITDA over the coming years, funded largely from internal accruals. Q1 FY27 delivered record quarterly revenue (₹188.91 crore) and a 16.8% operating margin.
What the company does
Asahi Songwon manufactures organic colour pigments and pharmaceutical active ingredients and sells them business-to-business. Its products are inputs, not consumer brands. The pigments business converts petrochemical-derived intermediates into high-purity colorants. The key inputs are phthalic anhydride, urea and copper salts for CPC blue crude (inferred from standard CPC chemistry). CARE Ratings separately notes a supply arrangement for phthalic anhydride (CARE, Nov 2020).
The colorants are sold to manufacturers of printing inks, packaging inks, paints and coatings, plastics masterbatches, textiles, rubber and paper. The API business manufactures bulk drug substances, including anticonvulsant, antipsychotic and antidiabetic molecules, and sells them to formulators. It is backward-integrated into key intermediates.
Company's own description (paraphrased from AR FY26)
The company describes itself as one of the established global manufacturers of phthalocyanine blue pigments. It says it is building two further businesses, in Azo pigments and in APIs. It frames the blue pigments business as its foundation, dependable in cash generation and market standing. It says the Azo and pharmaceutical businesses crossed an important threshold in FY26, each turning profitable at the operating level and reaching cash break-even.
The FY26 report is themed "Calibrated for growth". Its core message is that the heavy capital spending is complete. Management will now raise utilisation at newer plants, hold realisations and efficiency in blue pigments, convert backward integration into a durable cost advantage, and direct cash towards a lighter balance sheet.
Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | ~100% product sales (manufactured goods). No subscription, licensing or service revenue is disclosed. Minor other income: ₹6.70 crore in FY26 (AR FY26). |
| Sales channel | Direct B2B sales to multinational and domestic manufacturers. Long-term supply agreements with key customers have run for up to 18 years (AR FY26). |
| Customer count | 101 customers (FY26), up from 19 in 2014 (AR FY26) |
| Customer stickiness | 80% of business from repeat customers. Longest single-customer collaboration is 21 years. The company says it has lost no customers and had zero product returns in three decades (AR FY26 — company claims). |
| Export intensity | Exports were 69% of standalone revenue in FY26, up from 64% in FY25 (AR FY26) |
| End-market diversification | Revenue from the ink industry has fallen from more than 90% to about 45% of the total, as the company diversified into paints, plastics, textiles and pharma (AR FY26) |
| Pricing | Largely contract and negotiated pricing with raw-material pass-through. FY26 second-half realisation gains were partly supported by passing through higher raw-material prices (AR FY26 MD&A). |
Value-chain position
Blue pigments: The company is integrated from CPC blue crude (the key intermediate) to finished Beta Blue and Alpha Blue pigments. One tonne of finished Beta or Alpha blue needs about one tonne of crude, so in-house crude is the main cost and supply-security lever (AR FY26). Screener's company profile describes Asahi as the world's largest producer of CPC Blue crude. The AR uses the more cautious phrase "one of the larger producers of the crude globally". This difference is noted.
Azo pigments: These are mid-stream coupling-chemistry pigments (reds, yellows, oranges). Inputs are sourced within the Dahej chemical cluster (AR FY26).
APIs: Atlas is integrated into intermediates (for example, R-CMH, the key Pregabalin intermediate) at Chhatral. Finished API is made at the WHO-GMP-certified Odhav plant (AR FY26; acquisition press release, Apr 2022).
Customer types and end-markets
| End-market | Products used | Notes |
|---|---|---|
| Printing and packaging inks | Beta Blue (PB 15:3 type), Alpha Blue, Azo yellows and reds | Historically more than 90% of revenue; now about 45% (AR FY26) |
| Paints and coatings (architectural, automotive, industrial) | Beta and Alpha Blue, Azo | AR cites rising use of CPC blue in premium automotive and architectural coatings |
| Plastics and masterbatch | Blue and Azo | — |
| Textiles | Blue and Azo | — |
| Rubber and paper | Blue | — |
| Pharmaceuticals (generic formulators) | Pregabalin, Amisulpride, Levosulpiride, Gliclazide, Etoricoxib, Phenylephrine | Through Atlas Life Sciences |
Independent characterisation
Asahi Songwon is best understood as a cash-generative, high-utilisation niche commodity-specialty pigment franchise attached to two sub-scale growth options.
The franchise is phthalocyanine blue. Its economics are cyclical but structurally advantaged by India's shift to being the dominant global source of the category (over 70% of global phthalocyanine demand, per the AR). The two options are Azo pigments and APIs. Each has consumed capital and management attention since 2019-22 and contributed losses through FY23-FY25.
The equity story therefore hinges on three things:
-
Whether blue-pigment margins can be held in the mid-teens through the cycle.
-
Whether the subsidiaries can move from break-even to the 13–16% operating margins management targets.
-
Whether free cash flow keeps deleveraging the balance sheet.
The Q1 FY27 print (16.83% operating margin, net profit ₹19.2 crore) is the first strong evidence for that thesis. A single quarter is not yet proof that it is durable.
Strategy
Stated strategy themes (AR FY26, paraphrased)
-
"Calibrated for growth". The building phase is over. The task is to raise returns on installed capacity, business by business, and convert them into growth and a stronger balance sheet.
-
Phthalocyanine: "Protect and sustain". Utilisation is already high, so the priority is durable margins rather than new capacity. The levers are disciplined pricing, de-bottlenecking, internal efficiency and value-added customer work. Management sees peak standalone EBITDA potential of about ₹50–55 crore. The Q4 FY26 call indicated this was achievable by FY27.
-
Azo: "Raise utilisation, then expand". Lift utilisation towards the mid-80s, then spend ₹10–15 crore from internal accruals to add about 50% capacity. Win US and European export customers. Target a low-teens operating margin.
-
API: "Fill the plant, certify, add products". Raise finished-API utilisation at Chhatral from about one-third of potential. Obtain CEP certification by end FY27. Broaden the molecule slate (ten in development). Target a 15–16% operating margin over time.
-
Balance sheet. Keep cutting debt from the ~₹220 crore peak. Fund only small, high-return projects. Avoid large capital commitments.
Internal inconsistency on Azo utilisation. The Azo section of AR FY26 describes utilisation as "rising towards the mid-eighties". The growth-strategy page targets lifting it "from about 65%". The Q4 FY26 call (per arthneeti summary) guided from about 65% to 75–85% over three to four quarters. The 65% figure appears to be the current base.
Medium-term targets and guidance
| Target | Value | Timeframe | Source |
|---|---|---|---|
| Group revenue ambition | ₹1,000 crore | "Over the coming years" (unspecified) | AR FY26 |
| Consolidated EBITDA potential | About ₹100 crore | Unspecified | AR FY26 |
| Standalone (blue) EBITDA | ₹50–55 crore peak potential | FY27 per Q4 FY26 call | AR FY26; concall summary |
| Subsidiaries' peak revenue (Azo + API) | ₹250–280 crore, without further major capital | Unspecified | AR FY26 |
| Azo operating margin | Low teens | As volumes build | AR FY26 |
| API operating margin | 15–16% | Over time | AR FY26 |
| Azo utilisation | ~65% to 75–85% | Next 3–4 quarters (from mid-2026) | Q4 FY26 concall summary |
| Azo expansion capex | ₹10–15 crore, about +50% capacity | Triggered at ~85% utilisation | AR FY26 |
| API CEP certification | Granted | By end FY27 (31 Mar 2027) | AR FY26 |
| Funding | Largely internal accruals; no major capex planned | Ongoing | AR FY26 |
Initiatives in the last 24 months
| Initiative | Status / detail |
|---|---|
| Blue de-bottlenecking and efficiency programme | Ongoing. Management indicated in Jan 2025 that expected output gains would arrive in Q1 FY26 rather than Q4 FY25 (Q3 FY25 press release). |
| Azo debottlenecking and process optimisation | Undertaken in FY25 (FY25 Directors' Report) |
| Chhatral backward integration (API intermediates) | Commercial since 2023; 60–70% utilised |
| CEP filing for Pregabalin | In progress; expected by end FY27 |
| Leadership succession | Arjun Jaykrishna appointed CEO (May 2026) |
| Finance-function strengthening | New CFO (Jul 2026) |
| Sustainability | About 80% process water recycled; effluent treatment plants at all sites; ISO 14001:2015 environmental management certification (per letterhead) |
| Borrowing authority | A postal ballot in May–June 2026 sought shareholder approvals. Media reports (scanx headline) reference CEO appointment and ₹150 crore loan approval. |
| Extraordinary General Meeting | An EGM notice appears in exchange announcements around Aug 2026 (5paisa feed). |
Products & Services
Phthalocyanine pigments (parent company, Padra)
| Product | Description and key characteristics | Target customers / applications | Launch / capacity history | Pricing model |
|---|---|---|---|---|
| CPC Blue Crude (copper phthalocyanine crude) | Key intermediate for all phthalocyanine blue pigments. Made in-house, which secures cost and supply. Also sold externally. | Captive use plus pigment converters | Technical collaboration with Clariant in 2003; capacity enhanced in 2008 and 2016 | B2B, negotiated |
| Beta Blue (Pigment Blue 15:3 family) | Beta-crystal-form CPC blue, the industry workhorse cyan for process printing. Valued for colour strength, durability and semi-transparency. Third-party coverage (bottomstreet) identifies PB 15:3 as a primary product. | Printing and packaging ink majors; also coatings and plastics | Added in 2008; capacity expanded in 2010 | Contract or supply agreements with multinational ink makers |
| Alpha Blue (Pigment Blue 15:0 / 15:1 / 15:2 family) | Alpha-crystal-form CPC blue with a redder shade. Used in coatings, plastics and textiles. Specific CI grades not disclosed. | Paints, plastics, textiles | Added in 2016 as forward integration | B2B |
| Green pigments (historical) | Phthalocyanine green | Inks and coatings | Began in 1993; segment demerged in 2014 | — (no longer offered) |
Installed capacity for blue pigments (tonnes per annum) is not stated in the sources reviewed. Utilisation is 80–85% (AR FY26).
Azo pigments (Asahi Tennants Color Pvt. Ltd., Dahej)
| Product | Description | Target customers | Capacity / status |
|---|---|---|---|
| Azo red pigments | Coupling-chemistry organic reds. Specific CI numbers not disclosed. | Inks, paints, plastics, textiles; mainly domestic, with export approvals in progress for the US and Europe | Part of 2,400 TPA red-and-yellow capacity |
| Azo yellow pigments | Organic yellows | Same | Same |
| Azo orange pigments | Referenced in AR FY26 shade range | Same | — |
Status: utilisation is rising towards the mid-80s per AR FY26. A brownfield expansion of ₹10–15 crore is planned once utilisation reaches about 85%. It would lift capacity by about 50%, because civil and structural work is already in place (AR FY26).
Active pharmaceutical ingredients (Atlas Life Sciences)
| Molecule | Therapeutic class | Status | Notes |
|---|---|---|---|
| Pregabalin | Anticonvulsant / neuropathic pain | Flagship; majority of API volumes | Company says it is the market leader in Pregabalin. Prices fell 40–45% after the acquisition and recovered about 15% from the low in FY26. A CEP-grade (EU regulatory) Pregabalin is expected after certification, targeted by end FY27. |
| R-Compound (R-CMH, Pregabalin intermediate) | Key intermediate | In production at Chhatral | Gives backward integration and cost control |
| Amisulpride | Antipsychotic | Commercial | — |
| Levosulpiride | Antipsychotic / prokinetic | Commercial | — |
| Gliclazide | Antidiabetic (sulfonylurea) | Commercial | — |
| Etoricoxib | NSAID (COX-2 inhibitor) | Commercial; described as recent | — |
| Phenylephrine | Decongestant / vasopressor | Listed in AR FY26 product panel | — |
| Pipeline | Ten products under development, including six new molecules and intermediates for existing products | R&D | Run by a separate R&D centre (team of 11) plus Odhav labs |
Pricing model: B2B sales of bulk API to formulators (domestic and export). Molecule-level pricing is not disclosed.
Financial Narrative
Basis:
-
Revenue, EBITDA, PAT, EPS and net worth are from AR FY26 KPIs (consolidated, ₹ crore).
-
Gross profit, operating income and interest expense are from a third-party data aggregator (stockanalysis.com, consolidated, INR million converted to ₹ crore). Its revenue figures reconcile exactly to the AR.
-
PBT is before exceptional items.
Note on PAT versus EPS. AR "PAT" is total group profit, including the non-controlling interest in the 51% Azo JV. EPS reflects profit attributable to owners. Because the JV made losses, owners' profit exceeds total PAT. For example, FY25 EPS of ₹16.76 implies owners' profit of about ₹19.75 crore, versus AR PAT of ₹16.86 crore.
Income statement (₹ crore unless stated)
Notes:
Diluted EPS: equals basic EPS. There are no convertibles, warrants or ESOPs outstanding (shareholding pattern declarations, 31 Mar 2026).
FY24 PAT: of ₹15.64 crore is after an exceptional gain from monetising non-core land (₹47 crore realised in 9M FY24, per CARE). The core business was loss-making before exceptional items (PBT -₹7.70 crore).
FY26 dividend: of ₹1.50 was recommended by the board on 29 Jul 2026, subject to AGM approval on 30 Sep 2026.
Margins and growth (%)
Revenue CAGR FY22→FY26 (derived): 6.9% per year: FY22 growth of 45.0% is from the aggregator and reflects the FY21 base.
Cash flow
Aggregator growth-rate data (roic.ai) shows free cash flow declined 27% in the latest year. That is directionally consistent with lower FY26 operating cash flow.
Quarterly trajectory (₹ crore)
Q1 FY25 and Q3 FY25 are derived from disclosed sequential growth rates (Q2 FY25 press release: +5.46% QoQ; Q4 FY25 press release: +14.23% QoQ). They sum to the FY25 total of ₹562.36 crore.
Data-quality flag. One outlet (scanx.trade) headlined Q1 FY27 profit as "₹192 crore". This is a unit error. The filing reports ₹1,923.20 lakh, which is ₹19.23 crore.
Commentary on trends, inflections and drivers
FY22 to FY23: the down-cycle and the acquisition. Revenue grew 22.8% in FY23 to ₹504.55 crore, helped by the first-time consolidation of Atlas (acquired April 2022). EBITDA, however, collapsed from ₹37.56 crore to ₹11.14 crore (margin 9.0% to 2.2%), and the group posted a ₹18.47 crore loss. CARE attributed the deterioration to three causes:
-
An adverse industry environment in the standalone pigment business, as customers destocked after the post-COVID surge.
-
High losses at the Azo JV, where plant stabilisation was delayed.
-
Higher interest from acquisition debt. Interest expense rose from ₹4.09 crore to ₹13.17 crore.
EBITDA interest cover fell below 1x in FY23. This was the low point of the company's recent history.
FY24: trough revenue, an exceptional rescue. Revenue fell 15.5% to ₹426.24 crore as destocking continued (CARE: blue utilisation of only about 60% in FY24; Azo about 54%). PBT before exceptional items was still negative at -₹7.70 crore. Reported PAT of ₹15.64 crore was produced by the ₹47 crore monetisation of non-core land, which CARE noted was used to shore up liquidity. Credit ratings fell further to A-.
FY25: cyclical recovery. Revenue rose 31.9% to ₹562.36 crore and EBITDA nearly tripled to ₹60.22 crore (10.6% margin). This reflected restocking, industry consolidation and blue utilisation above 85% (CARE, Jan 2025). Net profit attributable to owners was broadly flat because of finance costs and subsidiary losses.
FY26: lower revenue, better quality. Revenue fell 4.8% to ₹535.48 crore on soft global demand and tariff disruption. EBITDA margin held at 10.4%, finance cost fell 25.65%, and both new verticals reached EBITDA break-even. Operating cash flow of ₹43.24 crore funded ₹38.00 crore of financing outflows (debt reduction plus dividend). The year had a weak first half (Q1 FY26 net profit about ₹3 crore) and a strong fourth quarter (EBITDA ₹23.02 crore at 15.6%).
Q1 FY27: the inflection. Record revenue of ₹188.91 crore (+26% YoY, +31% QoQ) came with an operating margin of 16.83%, the highest in at least seven quarters. The drivers were blue-pigment volume and realisation gains, plus API price recovery (API segment result margin 14.0%).
What to watch. Azo revenue fell to ₹17.02 crore (versus a FY26 quarterly average of about ₹19.7 crore) as raw-material spikes led customers to defer purchases (MD commentary, Aug 2026). Durability across Q2 to Q4 FY27 is the key question.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Business | Plant(s) |
|---|---|---|---|
Asahi Songwon Colors Limited | Parent (listed) | Phthalocyanine pigments: CPC blue crude, Beta Blue, Alpha Blue | Padra (Vadodara) |
Asahi Tennants Color Private Limited | Subsidiary (51% JV with Tennants Textile Colours, UK, per CARE) | Azo pigments (red, yellow, orange) | Dahej (Bharuch) |
Atlas Life Sciences Private Limited | Wholly owned subsidiary (100% since 26 Mar 2024) | APIs and intermediates | Odhav (Ahmedabad); Chhatral (Gandhinagar) |
Atlas Life Sciences (India) Private Limited | Wholly owned subsidiary | Not separately described | — |
Plutoeco Enviro Association | Associate | Not described; the name suggests a shared environmental / effluent association | — |
Revenue by Segment
| Segment (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Phthalocyanine pigments (standalone proxy; FY26 derived) | 276.58 | 390.22 | 343.60 |
Azo + API subsidiaries combined (derived) | 149.66 | 172.14 | 191.88 |
Consolidated revenue from operations | 426.24 | 562.36 | 535.48 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFY26 Vertical Detail Details
| FY26 vertical detail | Revenue (INR Cr) | % of consolidated | Profit / (loss) before tax (INR Cr) | Operating status | Source |
|---|---|---|---|---|---|
Phthalocyanine (derived) | ~343.60 | ~64.2% | ~31.3 (derived: consolidated PBT 25.56 plus subsidiary losses) | Q4 FY26 EBITDA margin 15.6% | AR FY26 |
Azo pigments (Asahi Tennants Color) | 78.94 | 14.7% | (2.42) | EBITDA-positive; cash break-even | AR FY26 |
API (Atlas Life Sciences) | 112.94 | 21.1% | (3.34) | EBITDA-positive; cash break-even | AR FY26 |
Consolidated | 535.48 | 100% | 25.56 (before exceptional items) | EBITDA ₹56.53 crore (10.43%) | AR FY26 |
Segment growth (%)
| Segment growth (%) | FY2025 | FY2026 |
|---|---|---|
Phthalocyanine (standalone proxy) | 41.1 | -11.9 |
Subsidiaries combined | 15.0 | 11.5 |
Consolidated | 31.9 | -4.8 |
Statutory Segment Details
| Statutory segment | Revenue (INR Cr) | Segment result (INR Cr) | Result margin (%) | Source |
|---|---|---|---|---|
Pigments (Phthalocyanine + Azo) | 155.16 | 23.08 | 14.9 | Q1 FY27 integrated filing (NSE iXBRL) |
API | 34.54 | 4.85 | 14.0 | Same |
Total | 189.70 | 27.93 | 14.7 | Same |
Vertical revenue, Q1 FY27 (INR Cr) | Amount | Source | — | — |
Phthalocyanine | 138.14 | Company press release via Indian Chemical News, 6 Aug 2026 | — | — |
Azo | 17.02 | Same | — | — |
API | 34.54 | Same | — | — |
Segment Overview
| Segment | Assets (INR Cr) | Liabilities (INR Cr) |
|---|---|---|
Pigments | 632.03 | 227.46 |
API | 172.30 | 146.81 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 410.82 | 504.55 | 426.24 | 562.36 | 535.48 |
Gross profit (INR Cr, aggregator) | 145.52 | 119.20 | 118.88 | 185.80 | 140.20 |
Operating income (INR Cr, aggregator) | 20.00 | -9.58 | 2.04 | 37.79 | 31.10 |
EBITDA incl. other income (INR Cr) | 37.56 | 11.14 | 21.07 | 60.22 | 56.53 |
Interest expense (INR Cr, aggregator) | 4.09 | 13.17 | 11.78 | 15.49 | 12.24 |
PBT before exceptional items (INR Cr) | 20.89 | -17.74 | -7.70 | 24.98 | 25.56 |
PAT, total group (INR Cr) | 14.65 | -18.47 | 15.64 | 16.86 | 17.78 |
EPS basic, owners (INR) | 16.10 | -9.83 | 17.01 | 16.76 | 15.92 |
Dividend per share for the year (INR) | 0.50 | 0.50 | 0.50 | 1.50 | 1.50 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 45.0 | 22.8 | -15.5 | 31.9 | -4.8 |
Gross margin (%, aggregator-derived) | 35.4 | 23.6 | 27.9 | 33.0 | 26.2 |
Operating margin (%, aggregator-derived) | 4.9 | -1.9 | 0.5 | 6.7 | 5.8 |
EBITDA margin (%, AR) | 9.0 | 2.2 | 4.9 | 10.6 | 10.4 |
Net (PAT) margin (%, AR) | 3.6 | -3.7 | 3.7 | 3.0 | 3.3 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net worth / total equity (INR Cr) | 284.43 | 260.05 | 265.95 | 282.50 | 297.88 |
Balance-sheet item (INR Cr) | FY2025 | FY2026 | Source / note | — | — |
Total assets | — | 603.01 | AR FY26 MD&A | — | — |
Non-current assets | — | 303.51 | AR FY26 | — | — |
Current assets | — | 299.50 | AR FY26 | — | — |
Current liabilities | — | 239.98 | AR FY26 | — | — |
Working capital (current assets less current liabilities) | — | 59.52 | Derived | — | — |
Non-current liabilities | 80.89 | 65.16 | AR FY26 | — | — |
Gross debt | ~163.9 (derived from debt/equity 0.58 × net worth) | ~140.0 (derived from debt/equity 0.47) | AR FY26 ratio table | — | — |
Net debt | — | 140.78 | AR FY26 highlights | — | — |
Cash and equivalents | — | Minimal (gross debt is close to net debt) | Derived | — | — |
Peak borrowings during investment cycle | ~220 | — | AR FY26 | — | — |
“—” = not publicly disclosed.
Cash-flow item (INR Cr)
| Cash-flow item (INR Cr) | FY2025 | FY2026 | Source |
|---|---|---|---|
Operating cash flow | 57.92 | 43.24 | AR FY26 |
Net cash used in investing (capex proxy) | — | 6.78 | AR FY26 |
Free cash flow (OCF less investing) | — | 36.46 | Derived |
Net cash used in financing | — | 38.00 | AR FY26 |
Dividends paid (cash) | ~5.9 (FY24 ₹0.50 × 1.1787 crore shares, paid Sep 2024; derived) | ~17.7 (FY25 ₹1.50 × 1.1787 crore shares, paid Sep 2025; derived) | Derived from DPS |
“—” = not publicly disclosed.
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing equity (%, derived from AR PAT) | 5.2 | -7.1 | 5.9 | 6.0 | 6.0 |
EBITDA interest coverage (x, derived) | 9.2 | 0.8 | 1.8 | 3.9 | 4.6 |
Ratio | FY2025 | FY2026 | Source | — | — |
Return on net worth (%) | 6 | 6 | AR FY26 | — | — |
ROA (PAT / total assets, %) | — | 2.9 | Derived | — | — |
ROIC (NOPAT / [equity + gross debt], %) | — | ~6.0 | Derived: EBIT ₹37.80 crore, ~30% tax, invested capital ~₹438 crore | — | — |
Current ratio (x) | 1.21 | 1.25 | AR FY26 | — | — |
Debt / equity (x) | 0.58 | 0.47 | AR FY26 | — | — |
Net debt / EBITDA (x) | ~2.7 (gross basis, derived) | 2.49 | Derived | — | — |
Operating (PBIT) margin (%) | 7 | 7 | AR FY26 | — | — |
Net profit margin (%) | 3 | 3 | AR FY26 | — | — |
Debtors turnover (x) | 4.14 | 3.73 | AR FY26 | — | — |
Inventory turnover (x) | 6.51 | 5.03 | AR FY26 | — | — |
Asset turnover (x) | — | 0.89 | Derived | — | — |
Days sales outstanding (days) | 88 | 98 | Derived (365 / debtors turnover) | — | — |
Days inventory (days) | 56 | 73 | Derived (365 / inventory turnover; AR basis not specified) | — | — |
“—” = not publicly disclosed.
Income Statement
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|
Consolidated revenue (INR Cr) | 134.27 | 141.61 | 133.72 | 152.75 | 144.05 | 188.91 |
Income Statement and Margin Analysis (%)
| Q1 FY27 snapshot | Q1 FY26 | Q4 FY26 | Q1 FY27 | Source |
|---|---|---|---|---|
Revenue (INR Cr) | ~149.9–151.3 (sources vary) | 144.05 | 188.91 | Business Standard; Kotak; Q1 FY27 filing |
EBITDA incl. other income (INR Cr) | ~12.0 (derived) | 23.02 | 32.60 | Indian Chemical News (company press release) |
Operating margin excl. other income (%) | 7.04 | 13.55 | 16.83 | multibagg.ai, from filing |
PBT (INR Cr) | ~4.2 | 15.07 | 25.34 | Business Standard |
Net profit attributable to owners (INR Cr) | 3.16 | 10.87 | 19.23 | Q1 FY27 filing via scanx / marketsmojo |
Standalone net profit (INR Cr) | 5.53 | — | 16.93 | Q1 FY27 filing via scanx |
Consolidated EPS (INR) | — | 9.22 | 16.32 | roic.ai; Kotak |
“—” = not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Region and Revenue by Region (%)
| Region (INR Cr, standalone) | FY2025 | FY2026 |
|---|---|---|
Export revenue (derived) | 249.74 | 237.08 |
Domestic revenue (derived) | 140.48 | 106.52 |
Export share (%) | 64 | 69 |
Region Overview
| Region | Markets disclosed |
|---|---|
Americas | USA, Brazil |
Europe | Spain, Belgium, UK, Italy, Germany |
Asia-Pacific | China, Taiwan, Japan, Korea, Indonesia, Thailand, Singapore, Philippines, Malaysia, Vietnam |
Middle East / Africa | UAE, South Africa |
Share Price History
| Date | Price (INR) | Context | Source |
|---|---|---|---|
18 Apr 2022 | 334.40 | Atlas acquisition announcement | IIFL |
21 Nov 2024 | 373.60 | Recovery phase; P/E about 44x | INDmoney |
15 Apr 2025 | 352.35 | — | Kotak |
20 Oct 2025 | 277.10 | One year before cut-off | TipRanks |
5 Dec 2025 | 255.75 | One-year return -39.4% | Equentis |
22 Jan 2026 | 222.80 | Six-month return -48.8% | Kotak Neo |
2 Apr 2026 | 207.60 | Near cycle low (52-week low ~₹179.64) | finanzen.ch |
12 Jun 2026 | 257.89 | Post-Q4 FY26 | Torus |
29 Jul 2026 | 354.60 | Q1 FY27 results day | marketsmojo |
7 Aug 2026 | 369.00 | Market cap ₹435.9 crore; P/E 12.5x; P/B 1.6x | 5paisa |
11 Aug 2026 | 338.10 | -4.99% on the day | IIFL |
21 Sep 2026 | 364.00 | Latest verified quote | Business Standard |
Share Price & Returns
| Horizon | Return | Basis |
|---|---|---|
One year | about +31% | Versus ₹277.10 on 20 Oct 2025 (derived) |
Three years | about -3% | As of Dec 2025 (Equentis); not updated to the cut-off |
Five years | about +11% | As of Dec 2025 (Equentis); not updated to the cut-off |
Lifetime high / low | ₹588.95 / ₹51.05 | Anand Rathi |
52-week range | High ~₹454–463, low ~₹179.64 | Aggregators differ: ₹453.70, ₹454.75, ₹462.90 |
Valuation Snapshot
| Multiple | Value | Calculation |
|---|---|---|
Market cap | ~₹429 crore | 11,787,262 shares × ₹364 |
Enterprise value | ~₹570 crore | Market cap plus FY26 net debt of ₹140.78 crore. EV is overstated if Q1 FY27 deleveraging is included, since the company reported strong deleveraging in Q1 FY27. |
P/E (TTM) | ~12.3x | TTM EPS of about ₹29.56 (FY26 ₹15.92 − Q1 FY26 ~₹2.68 + Q1 FY27 ₹16.32) |
P/E (FY26) | ~22.9x | FY26 EPS ₹15.92 |
EV / EBITDA (TTM) | ~7.4x | TTM EBITDA of about ₹77.1 crore (FY26 ₹56.53 − Q1 FY26 ~₹12.0 + Q1 FY27 ₹32.60) |
EV / Sales (TTM) | ~1.0x | TTM revenue of about ₹574 crore |
P/B | ~1.4x | FY26 net worth of ₹297.88 crore (₹252.7 per share; includes non-controlling interest). 5paisa shows 1.6x. |
Dividend yield | ~0.4% | ₹1.50 / ₹364 |
Dividend per share by payment year (INR)
| Dividend per share by payment year (INR) | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
DPS paid (INR) | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.50 | 0.50 | 0.50 | 0.50 | 1.50 |
Analyst Ratings & Targets
| Date | Long-term rating | Short-term rating | Action | Driver |
|---|---|---|---|---|
25 Oct 2019 | AA-; Stable | A1+ (also CP A1+) | Reaffirmed | Strong liquidity, comfortable leverage |
18 Nov 2020 | AA-; Stable | A1+ | Reaffirmed | — |
10 Nov 2021 | AA-; Stable | A1+ | Reaffirmed | — |
26 Apr 2022 | A+; Stable | A1+ | Downgrade | Acquisition debt |
14 Mar 2023 | A; Stable | A1 | Downgrade | Weak profitability; Azo JV losses |
5 Apr 2024 | A-; Stable | A2+ | Downgrade | Continued weak coverage; land sale aided liquidity |
17 Jan 2025 | A; Positive | A1 | Upgrade | Recovery; blue utilisation above 85% |
2025 (later review) | A; Positive | A1 | Reaffirmed | FY25 improvement |
Facility Type Details
| Facility type | Amount (INR Cr) |
|---|---|
Long-term | 17.49 |
Long-term / short-term | 131.00 |
Short-term | 19.00 |
Total | ~167.5 |
Analyst Conclusions
Management guidance (summary)
-
Hold blue-pigment margins and reach standalone EBITDA of ₹50–55 crore (FY27 per the Q4 FY26 call).
-
Lift Azo utilisation from about 65% to 75–85% within three to four quarters, then spend ₹10–15 crore on expansion.
-
Obtain API CEP certification by March 2027 and raise finished-API utilisation from about 30%.
-
Long-term ambitions: ₹1,000 crore revenue and about ₹100 crore EBITDA.
-
No major capex; continued deleveraging; funding from internal accruals.
-
The MD said in August 2026 that he expects the strong momentum to continue through FY27.
Consensus: no institutional consensus exists (not publicly disclosed).
Bull case
-
The blue franchise has re-based upward. Q1 FY27 phthalocyanine revenue of ₹138.14 crore is about 60% above the FY26 quarterly run-rate (derived from about ₹86 crore). Combined with 80–85% utilisation and weaker competitors exiting, this suggests the ₹50–55 crore standalone EBITDA guide is conservative.
-
Operating leverage in the subsidiaries is large. Chhatral finished-API runs at about 30% utilisation, and management sees ₹250–280 crore of subsidiary revenue at peak without major capex, versus ₹191.88 crore in FY26. The API segment already earned a 14.0% result margin in Q1 FY27. CEP certification would add a higher-value regulated-market channel.
-
Equity value should accrue from deleveraging. Net debt of ₹140.78 crore is falling. Free cash flow was about ₹36 crore in FY26, and management cited strong Q1 FY27 cash flows, at a modest EV/EBITDA of about 7.4x TTM. A CARE upgrade to A+ is plausible if FY27 tracks Q1.
Bear case
-
One quarter is not a trend. The company's history shows violent cyclicality: EBITDA was ₹60.22 crore in FY25, ₹11.14 crore in FY23, and Q1 FY26 net profit was about ₹3 crore. Q1 FY27 benefited from restocking and raw-material pass-through that can reverse.
-
Structural returns remain poor. ROE has been about 6% for three years, the Azo JV is still loss-making at the PBT level, and 49% of Azo upside belongs to the partner. Working-capital ratios deteriorated in FY26, with DSO lengthening to about 98 days.
-
Governance and key-person risk. The company is family-run, with a 30-year-old CEO, a founder-Chairperson who is also an executive MD, two CFO exits in three years, and negligible institutional ownership (0.33%). Disclosure inconsistencies and a lack of institutional oversight increase the discount investors may demand.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Q2 FY27 results | ~Late Oct / early Nov 2026 (expected 28 Oct, unconfirmed) | Whether the operating margin holds at or above 14%; blue realisations; Azo recovery after the Q1 deferrals |
| Q3 FY27 / Q4 FY27 results | Feb 2027 / May 2027 | Run-rate towards ₹50–55 crore standalone EBITDA |
| CEP certification (Pregabalin) | By 31 Mar 2027 (guided) | Grant or slippage |
| Azo utilisation reaching ~85% | 2,027 | Expansion capex trigger (₹10–15 crore) |
| Net debt trajectory | Quarterly | Gross debt-to-equity below 0.4x; finance cost below ₹10 crore annualised |
| CARE rating review | Typically annual (early 2027) | Upgrade from A; Positive |
| US tariff and trade policy | Ongoing | Export approvals for Azo; blue export demand |
| Pregabalin pricing | Ongoing | Sustainability of the ~15% recovery |
| New CFO's first full-year disclosures | FY27 | Quality of investor communication and working-capital discipline |
| EGM / postal ballot outcomes | 2,026 | Borrowing authorisations (₹150 crore reported) and their use |
Analyst verdict
Asahi Songwon Colors is a genuinely advantaged niche business wrapped in an historically disappointing capital-allocation record. That record is now being repaired, but has not yet been fully proven.
The core phthalocyanine blue business is the real asset. It is backward-integrated, runs at 80–85% utilisation while a larger domestic rival runs at 40%, and serves global ink majors under multi-decade relationships. It sits in a category where India now supplies more than 70% of world demand.
The 2019–2024 diversification wasted much of that franchise's earning power. The Azo JV and the Atlas API acquisition came at the worst point of their cycles. Debt rose to about ₹220 crore, CARE downgraded the company three times, and the business needed a ₹47 crore land sale to stay comfortable on liquidity.
FY26 marked the turn, though not in revenue, which fell 4.8%. The turn was in quality. Both subsidiaries reached EBITDA break-even, finance cost fell by a quarter, and the balance sheet de-risked. Q1 FY27's record quarter (operating margin 16.83%, net profit ₹19.2 crore) is the first period in which all three engines contributed at once.
At about ₹364, the stock trades at roughly 12x trailing earnings and about 7x trailing EV/EBITDA. That is undemanding if Q1 FY27 represents the new base, and expensive (about 23x FY26 EPS) if it was a restocking spike.
Our assessment is that the evidence favours a structurally higher, but still cyclical, earnings base. Blue-pigment EBITDA of ₹50–55 crore looks achievable. API operating leverage and CEP certification provide credible upside, while Azo remains the weakest link.
The investment case is therefore positive but conditional. It needs confirmation over the next two quarters that margins hold at or above 14%, that receivables normalise, and that net debt keeps falling.
Governance concerns — founder-family concentration, CFO turnover, negligible institutional ownership and patchy disclosure — justify a persistent discount to larger Indian specialty-chemical peers. They also mean position sizing should reflect illiquidity.
SOURCES CONSULTED (primary sources first)
-
Asahi Songwon Colors Ltd, Annual Report 2025-26 ("Calibrated for growth"), filed with NSE and BSE on 5 Sep 2026 (NSE archives: AR_31632_ASAHISONG_2025_2026).
-
Asahi Songwon Colors Ltd, Q1 FY27 integrated financial results filing (iXBRL), 29 Jul 2026 (NSE archives).
-
Company press releases: Q2 FY25 (5 Nov 2024, BSE); Q3 FY25 (31 Jan 2025); Q4 FY25 (9 May 2025); Q4 FY24 (31 May 2024, BSE); Atlas Life Sciences acquisition (18 Apr 2022).
-
BSE disclosure ASCL/SEC/2023-24/61: acquisition of remaining 22% of Atlas Life Sciences (Mar 2024).
-
Shareholding patterns as of 31 Dec 2025 and 31 Mar 2026 (company website and exchange data via Emkay and Vogue).
-
CARE Ratings press releases: 25 Oct 2019; 18 Nov 2020; 10 Nov 2021; 26 Apr 2022; 14 Mar 2023; 5 Apr 2024; 17 Jan 2025.
-
FY25 Directors' Report (reproduced by IIFL / indiainfoline).
-
Indian Chemical News: Q4 FY26 (1 Jun 2026); Q1 FY27 (6 Aug 2026); Atlas acquisition (Apr 2022).
-
Business Standard: quarterly results page (Sep 2026); Atlas acquisition article (Apr 2022).
-
Exchange-filing aggregators: scanx.trade, boardstewardship.com, marketsmojo, multibagg.ai, sahi.com, bottomstreet, arthneeti (Q4 FY26 concall summary), DSIJ (25 Aug 2026), HDFC Sky, Kotak Neo / Kotak Securities, ICICIdirect, Screener.in.
-
Market-data aggregators: stockanalysis.com (Asahi and Sudarshan income statements), roic.ai, TipRanks, Equentis, Equitymaster, Upstox, 5paisa, Bajaj Finserv Markets, Anand Rathi, finanzen.ch, Torus, Choice India, Business Today, INDmoney.
-
Peer data: Sudarshan Chemical Q4 FY26 (Quartr; Arihant Capital result update; NSE investor presentation); Meghmani Organics Q4 FY26 press release (NSE), FilingReader, Arihant Capital, Screener.
-
Industry data as cited within AR FY26: IMF World Economic Outlook Update (Jan 2026); IBEF Chemicals (2025); Fortune Business Insights, Organic Pigments Market (2025); Grand View Research, India API Market (2025).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / key dates | Background | Age |
|---|---|---|---|---|
Mrs. Paru M. Jaykrishna | Founder, Chairperson and Managing Director | Founder; re-appointed as Chairperson & MD for 1 Aug 2026 – 31 Jul 2029 (subject to AGM) | Bachelor's degree in Law, Philosophy and Sanskrit. First elected woman president of an Indian industry association in seven decades. Former director of the Tourism Corporation of Gujarat and SIDBI. | — |
Mr. Gokul M. Jaykrishna | Managing Director (CEO until 26 May 2026) | With the company since 1996; 17 years as MD and 8 years as CEO; re-appointed MD for 1 Aug 2026 – 31 Jul 2029 | Finance major (economics minor), Lehigh University; previously at Krieger Associates (New Jersey). Director of Arvind Ltd and The Anup Engineering. President of the All India Pigment Manufacturers Association; associated with FICCI Gujarat. | — |
Mr. Arjun G. Jaykrishna | CEO and Executive Director | CEO since May 2026; in charge of pigment marketing and plant operations | BS in Chemical Engineering (Sustainable Energy minor), Northwestern University; IB from UWCSEA Singapore. Previously at Deloitte (brownfield acquisitions) and DIC Japan. Son of Gokul Jaykrishna. | About 30 (scanx, citing the filing) |
Mr. Mitesh N. Patel | Executive Director | With the company since 2006; re-appointment for 25 Oct 2026 – 24 Oct 2029 proposed | More than 20 years in chemicals; previously SVP, Commercial and Strategy Execution | — |
Mr. Maulik P. Shah | Chief Financial Officer | Appointed 8 Jul 2026 | More than 20 years' experience, including at AIA Engineering and Hitachi | — |
Mr. Joseph Saji Varghese | Company Secretary and Compliance Officer | Current | — | — |
Mr. Jagdish Sheth | Joint MD of Atlas Life Sciences at acquisition (2022) | — | — | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Category (inferred where not labelled) | Other affiliations |
|---|---|---|
Paru M. Jaykrishna | Executive, Promoter, Chairperson | — |
Gokul M. Jaykrishna | Executive, Promoter, MD | Arvind Ltd; The Anup Engineering |
Arjun G. Jaykrishna | Executive, Promoter group, CEO | — |
Mitesh N. Patel | Executive Director | — |
Maulik Mehta | Non-executive (presumed independent) | Deputy MD, Deepak Nitrite; Independent Director, Transpek Industry |
Shivani R. Lakhia | Non-executive (presumed independent) | Advocate (17+ years) |
Samveg Lalbhai | Non-executive (presumed independent) | MD, Atul Ltd; boards of The Anup Engineering, Arvind Products, Bengal Tea & Fabrics |
Anil Jain | Non-executive (presumed independent) | MD, Ascent Finechem; board of Hester Biosciences |
Rupesh Shah | Independent Director (appointed 1 Jul 2026) | Five decades in ceramics and food processing |
Sanjay Srivastava | Independent Director (additional director from 29 Jul 2026; five-year term proposed at AGM) | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
May 2023 | CFO Narendra Rathi resigns (personal reasons) | — |
4 Apr 2026 | Independent Director Sudhin Bhagwandas Choksey resigns | Letter dated 4 Apr 2026 |
9 Apr 2026 | CFO Pratik Shah resigns with immediate effect (personal reasons) | Second CFO exit in three years |
26 May 2026 | Gokul Jaykrishna resigns as CEO (remains MD); Arjun Jaykrishna becomes CEO | Planned generational succession; resignation acceptance filed 17–18 Jun 2026 |
1 Jul 2026 | Rupesh Shah appointed Independent Director | Replaces the vacancy |
8 Jul 2026 | Maulik P. Shah appointed CFO | Fills a three-month vacancy |
29 Jul 2026 | Sanjay Srivastava appointed Additional (Independent) Director; re-appointment of Paru and Gokul Jaykrishna as MD-level executives from 1 Aug 2026 approved by the board | AGM resolutions 5–8 |
Shareholding Trend
| Holder category (%) | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Promoter and promoter group | 67.00 | 67.00 | 67.00 | 67.00 |
Foreign portfolio investors | 0.08 | 0.00 | 0.05 | 0.01 |
Other domestic institutions | 0.03 | 0.30 | 0.31 | 0.32 |
Bodies corporate | 4.21 | 3.83 | 3.71 | 3.02 |
Individuals (excluding promoters) | 18.50 | 18.88 | 18.69 | 19.19 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Description / positioning | Source of data |
|---|---|---|---|
Phthalocyanine blue | Meghmani Organics (India) | Among the top three phthalocyanine pigment producers globally (Screener profile). FY26 pigment revenue about ₹461 crore at 3.3% EBITDA margin; pigment utilisation 40% (Q4 FY26 press release). | MOL press release; FilingReader |
Phthalocyanine and broad organic pigments | Sudarshan Chemical Industries (India) | India's largest pigment company. Acquired the Heubach Group global pigments business (closed Mar 2025; Heubach had earlier acquired Clariant Pigments). FY26 consolidated revenue ₹9,787 crore. | Quartr; stockanalysis |
Global inks and pigments (customer and competitor) | DIC Corporation / Sun Chemical (Japan / US) | World's largest ink-and-pigment group; also an Asahi customer and collaborator. Acquired BASF's pigments business in 2021. | General industry knowledge; CARE |
Phthalocyanine and Azo (China) | Chinese producers (multiple, unnamed) | China accounts for more than half of global pigment production, particularly Azo (AR FY26). Aggressive price competition. | AR FY26 |
Phthalocyanine (India, unlisted / small-cap) | Other Gujarat phthalocyanine producers | India supplies more than 70% of global phthalocyanine demand. Capacity closures among weaker players occurred in the downturn (AR FY26). | AR FY26 |
Azo pigments (India) | Sudarshan; other organised and unorganised Indian Azo makers | AR FY26 says few organised Azo players operate in India | AR FY26 |
Inorganic and allied pigments | Ultramarine & Pigments (India) | Adjacent pigment player (ultramarine blue); limited direct overlap | General industry knowledge |
Global organic pigments | Heubach (now within Sudarshan), Toyo Ink, Clariant (exited pigments) | Global consolidation context | Sudarshan disclosures |
API — Pregabalin and CNS | — | Asahi (Atlas) claims Pregabalin market leadership; the basis is not specified | AR FY26 |
API — Chinese suppliers | Chinese API producers | Drove the 40–45% Pregabalin price collapse after 2022 (AR FY26) | AR FY26 |
Peer Comparison FY2026
| Metric | Asahi Songwon | Sudarshan Chemical (consolidated) | Meghmani Organics (standalone) | Meghmani — pigment segment only |
|---|---|---|---|---|
Revenue | 535.48 | 9,787.2 | 2,091.8 | ~461 |
Revenue growth YoY | -4.8% | +1.7% (as presented by company; reported basis up ~192% because Heubach was consolidated from Mar 2025) | +4% | Declined (Q2 FY26 -15% YoY) |
EBITDA | 56.53 | 579 (company adjusted) | 228.7 | ~15 (3.3% margin) |
EBITDA margin | 10.4% | ~5.9% adjusted (6.4% per aggregator) | ~10.9% | 3.3% |
Net profit | 17.78 | 115.8 | 125.3 | — |
Pigment capacity utilisation | Blue 80–85%; Azo ~65% rising | — | — | 40% |
Debt / equity | 0.47 | — | 0.47 (consolidated) | — |
“—” = not publicly disclosed.



